Clinical Trial Update: [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study of [177Lu]Lu-NeoB in combination with ribociclib and fulvestrant for ER-positive, HER2-negative, GRPR-positive advanced breast cancer is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• Ribociclib (ribociclib)
• [177Lu]Lu-NeoB

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Phase 1 | Status: RECRUITING